CIPLA.NS Cipla Limited Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
14:35
Jan 24
Jan 24
Public news priced in; no extra Cipla returns from partnership.
The author argues that because the Cipla news is already public, it is already priced in, so no additional returns can be expected from that news. This is an efficient-market rationale for avoiding Cipla based on that public catalyst. No specific timeframe or risk is stated.
MED
14:18
Jan 24
Jan 24
Cipla's Lilly tirzepatide partnership is underpriced long-term growth driver
Cipla is the exclusive India partner for Eli Lilly's blockbuster GLP-1 drug tirzepatide, which is scaling faster than any drug in history and addresses large under-penetrated obesity and diabetes markets. The author believes Cipla is plugged into this megatrend without R&D risk and will likely manufacture tirzepatide in India, with patent protection until 2036. This partnership is seen as a multi-year growth driver that the market is underpricing, potentially making Cipla the biggest pharma stock in India over the next 10 years.
HIGH
About CIPLA.NS Investor Commentary
Across the available history and selected sources, Buzzberg tracks CIPLA.NS (Cipla Limited) across 1 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: u/the_storm_rider, u/Heartyprofitcalm.